Premium
Treatment Changes among Users of Non‐Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Author(s) -
Hellfritzsch Maja,
Husted Steen Elkjær,
Grove Erik Lerkevang,
Rasmussen Lotte,
Poulsen Birgitte Klindt,
Johnsen Søren Paaske,
Hallas Jesper,
Pottegård Anton
Publication year - 2017
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12664
Subject(s) - discontinuation , medicine , atrial fibrillation , vitamin k antagonist , dabigatran , rivaroxaban , stroke (engine) , anticoagulant , warfarin , anesthesia , cardiology , mechanical engineering , engineering
Patients with atrial fibrillation discontinuing anticoagulant therapy are left unprotected against ischaemic stroke. Further, switching between oral anticoagulants may be associated with a transiently increased risk of bleeding or thromboembolism. However, there is a paucity of real‐life data on pattern of switching and discontinuation of oral anticoagulants. To address this, we conducted a nationwide drug utilization study including all registered Danish atrial fibrillation patients initiating a non‐ VKA oral anticoagulant ( NOAC ) between August 2011 and February 2016. We assessed changes in anticoagulant treatment, including switching between oral anticoagulants and discontinuation of NOAC s, and explored patient characteristics predicting these changes. We identified 50,632 patients with atrial fibrillation initiating NOAC therapy within the study period. The majority initiated dabigatran (49.9%) and one‐third had previously used VKA . Within 1 year, 10.1% switched to VKA , 4.8% switched to another NOAC and 14.4% discontinued treatment. The frequencies of switching to VKA and discontinuation were highest among NOAC users of young age (<55 years) and with low CHA 2 DS 2 ‐ VAS c score (=0). However, the majority of patients (87.3%) stopping NOAC treatment had a CHA 2 DS 2 ‐ VAS c score ≥1. We conclude that switching from VKA to NOAC , and to a lesser extent from NOAC to VKA , is common, as is early treatment discontinuation. The majority of treatment changes are observed in patients at increased risk of stroke. More research is warranted on the risks of bleeding and thromboembolism associated with switching and discontinuation of NOAC s as well as the underlying reasons why these treatment changes occur.